Podcasts about Alfredson

Dr Deb Muth 00:03Well, welcome back to Let’s Talk Wellness Now. I am your host, Dr. Deb. And what is the most talked-about peptides in functional medicine? aren’t actually FDA approved. Not because they don’t work, but because no one’s funded the research to prove it yet. The truth is, some of the compounds that dominate wellness forums, BPC-157, TB-500, thymosin beta-4, epitalin, occupy a fascinating space between breakthrough science and unregulated experimentation. In today’s episode, we’re stepping into that grey zone, the world of investigational peptides, to separate mechanism from marketing. I’m going to walk you through the science that actually shows and where it stops, how to evaluate claims when human data don’t yet exist, and the quality, purity, and safety red flags that you need to recognise. Dr Deb Muth 01:06I created it in a previous episode, so go check that one out. And why honesty is the most important prescription in peptide medicine. If you’ve ever wondered whether these research-only peptides are the frontier of healing or the next functional medicine fad, this episode is for you. So grab your cup of tea or coffee, get comfortable, and let’s talk about what it really means to use peptides that are promising but still under investigation. So we’re going to break just for a second here and have a word from our sponsor. It is because of them that we stay on the air. So thank you for this. And we will be right back. Did you know sweating can literally heal your cells? Infrared saunas don’t just relax you. They detox your body, balance hormones, and boost mitochondrial energy. I’m obsessed with my Health Tech sauna. And right now, you can save $500 with my code at healthtechhealth.com slash dr-muth-req-25. Dr. Deb Muth 02:15All right, guys, welcome back. Let’s dive into investigational peptides, the evidence gap. So the following peptides we’re about ready to discuss are extensively in integrative, functional, and regenerative medicine circles. They may have intriguing mechanisms and promising preclinical data. However, they lack FDA approval, and the evidence quality varies dramatically. from interesting preliminary research to essentially no human data at all. And this distinction is really critical for maintaining scientific integrity. So let’s talk about immune-modulating peptides. There’s thymus and alpha-1, and this is an international story on the thymic peptides. Thymusin alpha-1, known as TA1, is marketed internationally as zidaxin. Dr. Deb Muth 03:16It’s a 28-amino acid polypeptide originally isolated from thymusin fraction 5, which was extracted from bovine thymus tissue. Modern production uses synthetic peptide synthesis. The thymus gland is located behind the sternum and is the primary site for T cell maturation, and thymic peptides like TA1 play roles in human system development and regulation. Now, I love thymus peptides. I love thymus glandular products. I’ve used thymus glandular products for decades. Ground-up animal thymus gland is basically what it is. There are a couple of different supplement companies that I’ve used over the years that are amazing with this. And they do a fantastic job, and they really do help to support the immune system. So when thymus peptides came out, it was really exciting because it took the whole idea of thymus support to a new level. Dr. Deb Muth 04:17The mechanism actually behind the thymus in alpha-1 is complex and involves multiple aspects of immune function. At the cellular level, TA1 enhances T cell maturation and differentiation, particularly the development of helper T cells and cytotoxic T cells. It modulates T cell receptor expression and can influence the balance between Th1 cell-mediated immunity and Th2 humoral immunity responses. And it also enhances the natural killer cell activity and modulates dendritic cell function, which are critical for antigen presentation. and initiation of adaptive immune responses. And on the cytokine level, TA1 influences production of interleukin-2, IL-2, interferon gamma, IFN-γ, and interleukin-10, IL-10. Dr. Deb Muth 05:19These create immune modulatory rather than simple immune stimulatory effects. This is a very important distinction because TA1 appears to help balance the immune system rather than simply ramping this up, which theoretically makes it safer in conditions where immune overstimulation would be a problem, such as an autoimmune disease. Hashimoto’s, autoimmune, lupus, Sjogren’s, any of those autoimmune diseases, we don’t want to overstimulate their immune system. So you want to use a product like this that’s non-stimulating. Now, the regulatory status on TA1 is geographically variable and represents one of the challenges in discussing this peptide with patients. It is not FDA-approved in the United States. However, it is approved in several other countries for specific conditions. Dr. Deb Muth 06:19In Italy, it’s approved for the treatment of chronic hepatitis B and hepatitis C. In China, it’s approved for chronic hepatitis B and adjunct immune compromised patients receiving vaccinations or suffering from certain infections. It has an orphan drug designation in the United States for certain cancer indications, but its designation does not constitute approval. It simply provides regulatory incentives for further development. So the evidence base for thymosin alpha-1 is substantial in some areas but comes primarily from non-US populations and research groups, which creates challenges in evaluating quality and generalizable information. So in hepatitis B and C, multiple clinical trials, many conducted in China and Italy, have examined TA1 as an adjunct to antiviral therapy. Dr. Deb Muth 07:21A meta-analysis by Wu and colleagues published in the Journal of Viral Hepatitis in 2013 examined 23 randomized controlled trials, including over 2,000 patients with chronic hepatitis B. The analysis found that combining TA1 with nucleoside analogs like LAMVDUDE or an and TCAVAR improved the hepatitis antigen seroconversion rates by HBV DNA clearance compared to its nucleoside analogs alone. And the effect sizes were modest but statistically significant, with the HBE-AG seroconversion rates improving from about 24% with antivirals alone to 38% in combined therapy. Now in hepatitis C, early trials before the development of direct-acting antivirals showed that TA1 combined with interferon alpha improved sustained virological responses, and compared to interferon alpha, Dr. Deb Muth 08:30Furon alone, particularly in difficult-to-treat populations like those with a genotype one or a high viral load. However, the advent of highly effective direct acting antivirals that achieve SRV rates, sorry, SVR rates exceeding 95%, the role of TA1 in hepatitis C has become less clear. Now in sepsis and critical illness, more recent interest has focused on TA1 in severe cases of sepsis and septic shock. Ren and colleagues published a systematic review and meta-analysis in the Frontiers of Immunology in 2022, analyzing 18 randomized controlled trials, including 1787 patients with severe sepsis or septic shock the pooled analysis showed that ta1 administration was associated with reduced 28-day mortality relative risk at 0.70 meaning a 30 reduction in mortality compared to the standard care alone and the effect appeared Dr. Deb Muth 09:39most pronounced in patients with sepsis-induced immunosuppression measured by HLA-DR expression in monocytes. Now, this is amazing because going forward, we’re going to talk about something that’s commonly known as cytokine storm. Now, cytokine storm really became apparent since 2020 with the viral infection that we’re dealing with in the world today. But they were already looking at this kind of cytokine storm produced by sepsis or sepsis-induced immunosuppression. And it triggered this hyperinflammatory response called the cytokine storm. And many patients who survived the initial phase of the immune suppressed stata, characterized by a T cell exhaustion, reduced antigen presentation, and increased susceptibility to secondary infections. Thymusin alpha-1, TA1, may help restore this immune competence in this phase. However, it’s important to note that patient selection and timing are critical. Dr. Deb Muth 10:43Giving this immune stimulant during a hyperinflammatory phase could theoretically worsen outcomes. So you don’t want to give it to them while they’re in the flare up or the sepsis or the infection, but given to them during the immunosuppression phase afterwards might be beneficial. Now there is also some cancer immunotherapy that we see with TA1 and has been studied as an adjunct in cancer treatment with the hypothesis that it could enhance immune surveillance and response to tumors. And a comprehensive review of Garci and colleagues published in Expert Opinion on Biological Therapy in 2007 examined multiple trials in melanoma, lung cancer, hepatocellular carcinoma, and other malignancies. And the results were mixed. Some trials showed improvement in the immune parameters, increased CD4 in T-cells. improved lymphocyte proliferation responses and some actually showed trends toward improved progression free survival but overall survival benefits were inconsistent and the heterogeneity of the cancer types treatment protocols and outcome measures makes a definitive conclusion difficult as a vaccine adjunct several studies particularly from china have examined ta1 as an adjunct to enhance vaccine responses Dr. Deb Muth 12:11in immune-compromised populations, including the elderly, dialysis patients, and transplant recipients. The rationale is sound. These populations often mount suboptimal antibody responses to vaccines, and TA1’s immune-enhancing effects might improve protection. There are small trials. They have shown improvement in seroconversion rates of hepatitis B vaccines and influenza vaccine in these populations. And though large-scale confirmatory studies are limited, there is a possibility here. Now, on their safety profile, one of the appealing aspects of thymusin alpha-A TA1 is that it’s apparently favorable safety profile in clinical trials. There are some injection site reactions with a little redness, a mild discomfort, and most commonly reported adverse effects. is that their severe adverse events attributable to TA1 have been rare in published trials. However, comprehensive long-term safety data are limited Dr. Deb Muth 13:13And theoretically, concern exists that immune modulation could potentially trigger or exasperate autoimmune conditions in susceptible individuals. Though this hasn’t been clearly demonstrated in clinical trials, integrative medicine considerations for integrative practitioners concerning the thymus and alpha-1, several factors require careful thought. First, sourcing and quality control are critical concerns. Since it’s not FDA approved, TA1 available in the United States typically will come from a compounding pharmacy or an international supplier with variable quality assurance. And pharmaceutical grade product with certificates of analysis showing purity, sterility, and endotoxin testing is essential, but it is readily available from many of these companies. Second, patient selection matters immensely. TA1 should be considered in complex cases where conventional approaches have been insufficient, such as chronic viral infections not responding adequately Dr. Deb Muth 14:21to standard antivirals, post-viral syndromes with evidence of immune dysfunction, cancer patients with immune suppression in consultation with oncology, and it should generally be avoided in active autoimmune disease unless there’s a compelling rationale and close monitoring. Now, TA1 is not a standalone therapy. In cases of chronic viral infection, Comprehensive immune support includes addressing nutritional deficiencies, optimizing vitamin D levels to be between 50 and 80, adequate zinc, selenium, and vitamin A, optimizing gut health since 80% of our immune function is in the gut, you need to optimize gut function. Managing stress from the HPA access dysfunction, chronic cortisol elevation, suppression, and immunity, ensuring adequate sleep, immune memory consolidations during sleep, addressing any metabolic dysfunction, insulin resistance, repairs in the immune function, and the bottom line on thymus and alpha-1 is Dr. Deb Muth 15:26is that it represents legitimate medicine in other countries with a substantial evidence base in specific contexts, but it remains experimental in the U.S., and practitioners using it should provide comprehensive, informed consent about its regulatory status, evidence quality, and source verification. while ensuring it’s part of comprehensive protocols. It is not a magic bullet. And again, what you’re gonna hear me say quite often here is that many of these peptides should be used in conjunction with something else. They should not be used alone. And can peptides be stacked? The answer is yes, they can. So if somebody has an insulin resistance, or a metabolic dysfunction, they can tier TA1 with a GLP-1 like terzepatide or semiglutide. That is not a problem to do that. You need to just work with a practitioner that understands how to do that effectively. So let’s look at BPC-157. Dr. Deb Muth 16:26This is a phenomenon I love BPC-157. Let’s separate it from marketing to actual mechanism of actions here. So BPC-157 stands for Body Protection Compound 157. It is a chain of 15 amino acids that are described as a partial sequence of body protection compound, a protein found in human gastric juice. It has become one of the most hyped peptides in regenerative medicine inside the athletic performance and biohacking communities with claims ranging from healing tendons and ligaments to repairing gut lining or reversing organ damage. The challenge is separating the legitimate mechanisms of science from the marketing hype. The proposed mechanism of BPC-157 are biologically plausible and intriguing. The research suggests that it may influence several growth factor pathways, including vascular endothelial growth factor, VEGF, which promotes new blood vessel formation and has improved better supply of blood flow to injured tissues, theoretically accelerating healing. Dr. Deb Muth 17:40It may also affect fibrous blast growth factor, FGF, and transforming growth factor beta, TGF beta pathways. both involved in tissue repair and remodeling. And some studies actually suggest that BPC-157 modulates inflammatory cascades, potentially reducing excessive inflammation while promoting the resolution phase that allows tissue rebuilding. Now I want to talk just a few moments here about these different tests that we’re talking about tgf beta veg f for those of you who are in our mold world you are very familiar with these uh lab tests we do this to see if you have a mold exposure what’s happening to your body and it’s been very challenging to try to heal this part of the mold illness and manipulate these VEGFs and TGF betas. And so with the fact that BPC helps us modulate this inflammatory cascade, BPC can be very helpful in the world of mold or mycotoxin illness in repairing those parts of the body that have been damaged by the mycotoxins. Dr. Deb Muth 18:48Now there is animal research on BPC-157. It is extensive and primarily from a research group led by pre-drag, oh, I can never say these names, Cyrek at the University of Zagreb in Croatia. Published studies in animal models have shown accelerated healing in a remarkable variety of injury types. A 2011 paper by Chang and colleagues in the Journal of Applied Physiology demonstrated that BPC-157 improved therapy tendon healing in rats with Achilles tendon injuries, and the treated rats showed increased tendon outgrowth, better cell survival in the injured area, enhanced cell migration to the injury site, and improved biochemical strength of the healed tendon compared to controls. Multiple other animal studies have shown similar promising effects. Ligament tears, healing faster in rabbits, muscle damage recovering more quickly in rodent models, gastric ulcers healing in rats given experimental induced ulcerations, inflammatory bowel lesions improving in mouse models of colitis, and even bone to tendon healing showing enhancement in animal studies. Dr. Deb Muth 20:02The breadth of injury types showing benefit in preclinical models explains the enthusiasm of this peptide. However, this is critical. These animal studies, primarily in rodents and rabbits, animal models of injury healing don’t reliably translate to human clinical outcomes. And the doses used in these animal studies when converted to human equivalent doses vary widely. And optimal human dosing is completely unknown at this point. it is all considered experimental and perhaps most importantly there are essentially no peer-reviewed controlled clinical trials in human published in humans published in major medical journals in a 2001 review of arthroscopy and the journal of arthroscopic and related surgery specifically examined in the evidence of bpc 157 and other peptides in musculoskeletal medicine The authors concluded bluntly that BPC-157 lacks evidence from randomized controlled trials and has an unknown safety profile in humans. Dr. Deb Muth 21:09 They emphasized that the jump from animal data to recommending peptides for humans use bypasses the fundamental requirement for Phase I safety studies, Phase II dose-finding studies, and Phase III efficacy trials that would establish whether BPC-157 actually works in humans and whether or not it’s safe. The absence of human safety data is particularly concerning given BPC-157’s proposed mechanisms. Peptides that influence growth factor signaling and angiogenesis could theoretically have off-target effects. Uncontrolled angiogenesis, for instance, is a hallmark of cancer progression. Tumors require blood vessel formation to grow beyond a certain size. And while there’s no evidence that BPC 157 promotes cancer, The complete absence of long term human safety studies means we simply don’t know. This isn’t fear mongering. It’s acknowledging uncertainty and uncertainty exists and understanding that if you’re choosing to use peptides like BPC 157, you are doing it in an experimental model. Dr. Deb Muth 22:17We’re experimenting with the doses that are being used. And there is potential for it to cause cancer cells in your body to grow. And you need to be aware of this and understand the risks that you’re taking when you’re using an investigational or off label use peptide. Now, quality control issues with BPC also exist. It’s not FDA approved for any indication in the US. It’s not approved in any major regulatory jurisdiction worldwide. It’s marketed as a research chemical explicitly to bypass FDA oversight. And commercial sources selling BPC-157 range from compounding pharmacies, which have some quality standards but are not FDA inspected. You can take that for what you want to believe on that one. to overseas suppliers operating with absolutely no quality assurance whatsoever. If you are choosing to use BPC-157, you have to understand who’s manufacturing it for you, where you are getting it from, how pure it is. Dr. Deb Muth 23:26You want to make sure that you have the certificate of analysis and that it does not contain bacterial endotoxins that can contaminate the peptide or degrade the peptide and cause other issues for you. So when you talk about peptides with patients regarding BPC-157 or if you’re listening to this and you’re already using BPC-157 or other peptides, that are quote-unquote not for human consumption, an evidence-based response acknowledges both the appeal and the limitations. And you want to talk about the animal data that’s definitely showing some progress and some potential, but we don’t know what we don’t know in humans. If people are willing to take that risk, that is up to them to do that. But using BPC right now is experimental and people need to be aware of that. Are there evidence-based alternatives for patients with tendon or ligament injuries? Dr. Deb Muth 24:26And there are. There’s PRP, which has been studied in multiple randomized controlled trials. for conditions like lateral epicondylitis, tennis elbow, Achilles issues, patellar issues, knee issues. However, I want to caution you on this too. So the study that was done by Cox and colleagues in muscles, ligaments, and tendons in the Journal of 2014 showed modest benefits in pain and function compared to controls. And though the effects vary by injury type, PRP preparations can be helpful. You have to understand that a lot of times when people are doing PRP injections in their office, they are not doing it exactly the same way it was done in the study. And not to mention, if you’re using your own PRP to heal a ligament or a tendon or help your arthritis and you’re 60 or 70 years old, That is not good quality protein rich plasma. It is old protein rich plasma. And you’re not going to see necessarily the same benefits that you would see if you were using placental tissue or umbilical tissue. Dr. Deb Muth 25:33You also want to address the nutritional deficiencies or support that’s needed for connective tissue healing. And these are collagen peptides dosed at 15 grams a day. And this has been shown in a study by Shaw and colleagues in the American Journal of Clinical Nutrition in 2017 to augment collagen synthesis when combined with intermittent loading. Vitamin C is also an essential cofactor for collagen production and stabilization of collagen structure at a dose of around 500 to 1000 milligrams a day to support this process. You also need to have good adequate intake of copper and zinc. These are cofactors in collagen. Silica is also important. This comes from horsetail extract. This provides additional support as well. So more importantly, I think remembering that rehabilitation matters as well. Doing these protocols without doing some rehab is not going to get you where you want to go. Dr. Deb Muth 26:33There’s a research study by Alfredson and others for Achilles tendinopathy using the control lengthening of muscle tendon units under load to promote tendon remodeling and healing. These protocols have solid evidence and cost nothing beyond professional guidance from a physical therapist. They are important for patients seeking cutting edge regenerative approaches. Stem cell therapies, growth factors, concentrates derived from patients’ own tissues like PRP. These have a lot of good endogenous materials and they have good safety profiles. BPC-157 represents the perfect example of how promising Preclinical science gets marketed far beyond the evidence and it may eventually prove to be valuable. I think it will. But right now that determination does require some human studies and hopefully with the administration that we have right now and Bobby Kennedy, we will actually start to see some of that occur. Now the next peptide I want to talk about is TB4, thymus and beta-4. Dr. Deb Muth 27:36This is a wound healing peptide. It is a 43 amino acid peptide that’s naturally present in virtually all human cells except red blood cells. It’s actually one of the most abundant peptides in the human body, particularly concentrated in blood platelets, wound fluid, and many tissues. It’s naturally ubiquity makes it mechanistically interesting. The body wouldn’t produce it in such abundance if it didn’t serve a function. So the primary role of TB4 involves building G-actin. It’s a form of monomeric actin. And it’s structural protein that forms the microfilaments within the cells, providing cellular structure and enabling cell movement. TB4 prevents from F-actin filaments. I’m not going to talk too much about this. It’s really critical for wound healing as cells need to migrate into the injury sites. Dr. Deb Muth 28:37so the cell shape changes and the cellular response to the injury. So think of this as though you tore your meniscus and the body created all this TB4 to come to that injury to try to heal that site. That’s exactly what the TB4 is doing inside the body when there’s an injury. It’s been shown in research to help produce new blood vessel formation, promote endothelial cells, It helps modulate inflammatory cytokines, potentially reducing TNF-alpha, IL-1, and possibly protecting in programmed cell death, which we call apoptosis. And some studies suggest that it is cardioprotective in its effects in animal models of myocardial infarction, so heart attack, and neuroprotective in other models for brain injury. Now, these remain to be preliminary, but they are being seen. So the regulatory status on TB4 can create some confusion. Dr. Deb Muth 29:40The natural TB4 molecule itself is not FDA approved as a drug. However, TB4 based drug candidates called RGN259, formerly TB4, has been in the development by regen tree for corneal injuries of the dry eye disease. And as of recent updates, this drug is completed phase three trials for its neurotrophic keratopathy, severe corneal condition. But the FDA approval is still pending. So that means that the most advanced TB4-based pharmaceuticals hasn’t yet crossed the finish line for approval. The commercial peptide market further muddies the picture with TB500, which is often described as the synthetic fragment of TB4. However, this extract’s relationship between TB500 and TB4 varies depending on the source. Dr. Deb Muth 30:41So some claim that TB500 is identical to TB4, but positions 1 through 4 suggest it’s a different fragment. and the quality control across suppliers is not existent. So this confusion is part of why recommending TB500 becomes problematic for practitioners and patients, often because they aren’t certain what molecule they’re actually getting. The evidence base for TB4 in humans is limited, primarily to eye research, and the studies from Sohn’s and colleagues published in journals like Vitamins and Hormones in 2016 have examined topical TB4 for corneal injuries and neurotrophic keratopathy, dry eye, and other surface diseases. Now, these studies showed some promise in promoting this, and there is, however, a topical application to the cornea that is vastly different from a systemic injection. So for systemic use in wound healing, musculoskeletal issues, Dr. Deb Muth 31:42cardiac protection, neuroprotection, human clinical trials. There is scarce to non-existent evidence in humans. Most of the evidence remains in animal models or cell culture studies. And a review by Flip and colleagues in the Journal of Investigational Dermatology in 2006 detailed TB4’s effects on the matrix remodeling during wound repair in animal models, showing effects on collagen disposition, granulation, tissue reformation, and wound contraction. Another review by Ho and colleagues in expert opinion on biological therapy in 2007 discussed TB4’s potential in tissue regeneration and regenerative medicine, but noted the field remained largely blank. preclinical. So this is really important again to understand that there is just not enough human data. So there is a concern with cell division and migration. This theoretically exists Dr. Deb Muth 32:45for the potential effects on cancer cells, which would also rely on migration and division and other intended consequences of disrupting normal cellular architecture. These aren’t proven risks, but they are unexplored questions that we need to be aware of when we’re using peptides. This can cause cancerous tissue to grow. Very similar to what we talked about with BPC-157. These are also sold as research chemicals. There is no FDA oversight. So purity, potency, contaminations all still exist for these peptides. Now from an integrative perspective, the natural presence of TB4 in wound fluid and its biological roles in healing are legitimate science. in presence does not equal therapeutic utility. The body tightly regulates where and when and how much TB4 is present through natural production and bypassing that regulation with external dosing may or may not cause us to have beneficial or introduce risk. Dr. Deb Muth 33:49So we need to know that this is experimental use. Those people who are seeking wound healing and tissue repair the evidence-based approach of the body’s own capacity to heal is huge definitely want to be increasing your protein intake optimizing your zinc copper vitamin c and vitamin a and then managing glucose is really important during this time as well so let’s talk about a fun topic now and that’s growth hormone secretagogues this is the anti-aging hype machine these peptides in this category are things like semoralin ipameralin cjc 1220 1295 and others and among the most aggressively marketed in anti-aging and longevity medicine they all share a common goal stimulating the pituitary gland to release more growth hormone and the appeal is understandable. GH levels decline with age, and this decline is associated with increased fat mass, decreased lean muscle, reduced bone density, and other aspects of aging. Dr. Deb Muth 34:55The other times we’ll see growth hormone levels decline significantly is with chronic illness, and the logic is to restore youthful GH levels and youthful physiology. Now, semirelin from an FDA approved diagnostic to compound anti-aging product. Semirelin is a 29 amino acid peptide representing the first 29 amino acids of the full 44 amino acid human growth releasing hormone, GHRH. We talked about this on another episode of the podcast. And you can go back and listen to that one a little bit if you want. This fragment contains the complete biological activity of the full GHRH molecule and it binds to GHRH receptors in the anterior pituitary and stimulates growth releasing peptides, growth hormone releasing peptides. Semirelin was previously FDA approved as diagnostic testing of growth hormone secretion, essentially, to determine if the pituitary could still respond to GHRH stimulation in patients being evaluated for growth hormone deficiency. Dr. Deb Muth 36:06However, the manufacturer was discontinued and there was no longer an FDA approved semirelin product on the market in the United States. What exists now is semirelin available from compounding pharmacies used off label for anti-aging, body composition, and general growth hormone optimization purposes. This represents a significant gray area. Again, compounding medications serve a very important role, but they need to meet certain recommendations and regulations, as we’ve talked about in the past. You want to make sure that your compounding pharmacy that you’re obtaining semirelin from is qualified to do that, that they are doing best practices, and that you’re getting a good product. The theoretical advantage to semirelin over direct growth hormone administration is that it preserves more of the physiological growth hormone secretion patterns. Natural GH is released in pulses, primarily during sleep, not as a continuous elevation. Dr. Deb Muth 37:07So semirelin stimulates the pulses rather than providing a constant super physiological growth hormone level. And that pulsatile pattern is thought to reduce some of the side effects and metabolic concerns that we have with continuous growth hormone exposure. However, the evidence supporting semirelin for anti-aging and body composition in healthy adults is minimal. Most of the data comes from studies conducted in the 1990s when the FDA approved product existed. Not that that means it’s bad. We have drugs that have been in the market for over a hundred years that are still there, that still have the research and are still being used successfully and safely today. So we don’t want to let that really make us think that this product isn’t safe. So a 2006 review from Walker in Clinical Interventions of Aging suggested that semirelin might be a better approach than direct GH for adult onset growth hormone insufficiency, but they do acknowledge that the evidence was limited. Dr. Deb Muth 38:12And although we don’t have any large scale trials that we can examine for semirelin’s efficacy, it is now commonly prescribed. And the optimal dosing for anti-aging purposes is still unknown. It is considered experimental and it does vary from person to person, but it is still unstudied. The effects on cancer risk, cardiovascular disease, metabolic dysfunction over long time periods are also still unknown. I would argue that the side effects or the risk factors of not having growth hormone are equally as bad as the unknowns that we have here. We’re not looking to try to get super physiological doses. We’re trying to restore youthful GH levels. Typically, we’re not trying to restore back to a 20-year-old. We’re trying to restore back maybe 10 years. That is a better way of doing this. And I think that’s important for people to understand. Now, ipamirelin is the ghrelin mimicker. Dr. Deb Muth 39:12Ipamirelin is a pent-up peptide, five amino acid, that acts as a growth hormone secretagogue receptor, a GHS-R agonist. It mimics the action of ghrelin, the hunger hormone, that also stimulates growth hormone release. The proposed advantage over earlier secretagogues is that ipamirelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or other glucose things, which can be increased by growth hormone secretagogues. The regulatory status is clear. Ipamirelin is not FDA approved for any indication. It’s sold as a research chemical. Human evidence is thin. It’s limited to single dose studies examining how quickly it’s absorbed and metabolized with minimal data on dosing and clinical outcomes. Now there are marketing claims for ipamirelin and they are extensive. Dr. Deb Muth 40:13It increases lean muscle mass, it decreases body fat, it improves sleep quality, faster recovery from workouts, enhanced injury healing, better skin quality. The evidence supporting these claims in humans is not available we don’t have it these are claims that are made by the effects that we know from growth hormone so it’s not necessarily a bad thing we know what growth hormone does we know growth hormone does all of these things if ipamorelin is a precursor to that it will obviously help improve those things making that correlation of what growth hormone does So there are safety concerns that mirror the same as any other growth hormone elevating therapy. It can cause fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, glucose intolerance, and theoretically, can it increase calcium? cancer risks? It can because IGF-1 promotes cell proliferation and can inhibit apoptosis in cancer cells. Now remember, your body makes IGF-1. Dr. Deb Muth 41:15If it’s not making enough of it, that’s a problem. If it’s making too much of it, That’s a problem. So just understand that if you are adding these things, and especially in elevated doses, you are taking a potential risk. So there is also now CJC 1295 is a modified GHRH analog of 30 amino acid peptide based on GHRH structure, but with modifications. So it includes the addition of drug affinity complex, DACC, DAC, which involves conjugation with a small albumin binding molecule, dramatically extends the peptide’s half-life from minutes to as much as potentially a week or more. And this creates sustained growth hormone elevation rather than that pulsatile release. There are actually two versions of this. There’s CJC 1295 with DAC, longer acting version, and CJC 1295 without DAC, which is essentially a shorter duration of semirelin. Dr. Deb Muth 42:19And so when we’re comparing products, it is… only the difference between long acting and short acting. The human evidence for CJC 1295 is limited to a single published phase one study by Techman and colleagues in the Journal of Clinical Nutrition and Metabolism in 2006. And the study involves 18 healthy young adults showed that CJC 1295 with DAC produced a sustained elevation of GH and IGF-1 lasting several days after the injection. That’s essentially the entire published human evidence of this peptide. There are no phase two studies examining optimal dose. So that is all considered experimental. And there is no phase three studies examining clinical efficacy. So the sustained GH levels created by CJC 1295 with DAC raises specific concerns because the natural GH secretion It goes up and down, up and down, up and down. Dr. Deb Muth 43:19And that constant elevation may have a different metabolic and cellular effect. And we just really don’t know what that’s going to be yet. So we can understand that elevated IGF-1 levels can theoretically increase cancer concerns and metabolic risks. So rather than always injecting peptides, which are very expensive… You can do other things. And there was a study by Hartman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 1992 that demonstrated the 48-hour fast increased integrated growth hormone secretion five-fold through increased GH levels. Now, the problem with this is fasting for 48 hours is a challenge. And how long is it going to increase the growth hormone secretion without causing issues? Or in general, how long is it going to go up? Dr. Deb Muth 44:19So we have to be cautious about that as well. Sleep optimization is non-negotiable. The majority of growth hormone secretion occurs during sleep, slow wave sleep, typically the first sleep cycle, and poor sleep quality or insufficient sleep typically. can dramatically affect your growth hormone levels. And then high intensity interval training, HIIT resistance training can stimulate growth hormone as well. This was seen in a study by Godfrey and colleagues in sports medicine in 2003 and was examined in exercise-induced growth hormone responses to athletes. So we definitely see these kinds of things. So let’s talk about some longevity peptides now. These expand the telomere. So there’s epitalin and epithalamin and when these are used in anti-aging they can produce some amazing results. Dr. Deb Muth 45:22So epitalin is a synthetic terapeptide, just four amino acids. It was originally synthesized as a simplified version of epithalamine. a pineal gland extract containing multiple peptides. The synthetic four amino acid version was created to isolate what researchers believed might be the active anti-aging component. The mechanism produced for epitalin centers on telomere and telomerase, Telomeres are protective caps at the end of the chromosomes consisting of repetitive DNA sequencing. And every time a cell divides, telomeres shorten slightly because DNA polymers cannot fully replicate the ends of the linear chromosomes. So this progressive shortening acts as a molecular clock. After 50 or 70 divisions, the telomeres become critically short, triggering a cellular senescence. Dr. Deb Muth 46:22This telomere shortening is one mechanism of cellular aging and telomeres in the enzyme that can rebuild telomeres by adding these caps back onto the end of the chromosome. It’s active in stem cells, germ cells, and unfortunately in about 85 to 90% of the cancer cells. In most adult somatic cells, telomerase is inactive or present at very low levels, allowing the telomeres to shorten with division. The research on epitalin suggests it might activate this telomeres act telomeres process primarily from a research group led by Vladimir in Russia. Vladimir Kavasan in Russia. He is a huge peptide researcher or was he passed away with publications dating back to the early 2000s and a study published in bio gerontology in 2000 by Kavasan Dr. Deb Muth 47:25and colleagues examined the effect of epitalin on the lifespan of fruit flies, and they treated fruit flies that showed a modest increase in mean and maximum lifespan compared to its controls by approximately 10 to 15% lifespan extension in some experimental groups. And there were other studies in 2003 that examined epitalamine in a female Swiss-derived mouse. This was done by Ann Simove and colleagues. And the researchers reported that epitalin treatment was associated with increased lifespan as well. And the most cited mechanistic work comes from cell culture studies. And that is also Cavason’s group that published this research in 2003, showing increased telomeres activity in cultured somatic cells again. More recently, between 20 and 25, the series of publications have continued to explore epithelial effects on telomere dynamics in cell cultures. Dr. Deb Muth 48:32So there is a lot of research that’s been done. The mass majority has been done on epithelin. And most of it has been done by a single research group in Russia. There is some restrictions on some of the cell culture data that we’re seeing. And it does show that epithelin sometimes can be described as a regulating hormone. Carcadian rhythm for melatonin production, which is derived by the penile extracts. And however the evidence for this affects minimally and mechanistically unclear, the pineal gland primarily functions as melatonin secretion in that light-dark cycles. So Epithalin or epitalin is not FDA approved. It is not approved for any major regulatory jurisdiction. It is sold as a research chemical only. Dr. Deb Muth 49:33So you need to follow the same safety profiles that we’ve talked about in other episodes and in today’s episodes. And when we’re talking about epithalin, and we’re excited about it being an anti-aging science, we should balance this with the honesty and the evidence of the quality of that evidence. We don’t know its safety effect. We don’t know if it’s going to increase the risk of cancer. We can’t verify that. And we need to be using it in an experimental use of unknown risks only. Of course, diet, physical activity, stress management, sleep quality, all of those things are important for us to be looking at when we’re looking at these peptides. Now, I want to get into some of the brain peptides. This is the nootrophic frontier. C-Max and C-Lank, there is Russian pharmacology that’s done. C-Max and C-Lank represent an interesting case study in how different regulatory environments and research traditions Dr. Deb Muth 50:36create challenges in evaluating this evidence. Both peptides were developed in Russia, are approved for their specific indications and have substantial Russian language and literature supporting their use. However, the FDA approval in the United States is still not there. C-Max is a seven amino acid. It’s a synthetic analog. It is a fragment, particularly ACTH 4 through 10. It’s sometimes called the melanocortin effects because it involves the melanocortin receptors of the central nervous system. CMAX was developed by the Institute of Molecular Genetics of Russia Academy of Sciences and is approved in Russia for several indications, including acute stroke, transient ischemic attacks, cognitive disorders. It has Russian approval and is based on clinical trials primarily in Russia. Dr. Deb Muth 51:39It does help to increase brain-derived neurotrophic factor, BDNF, a protein critical for neuroplasticity, the brain’s ability to form new connections and adapt to the challenges. BDNF supports neuronal survival and promotes growth of these new neurons. C-Max also influences neurotransmitter systems, particularly dopamine and serotonin, and there is some research that suggests it affects on metabolism as well, and endogenous opioid peptides that involve pain reception and mood regulation. So it has some good potentials there. There is also C-Link, which is a hepatopeptide structurally similar to Tufts’ and an immune modulatory peptide. It was also developed in Russia and was approved for anxiety disorders as a neurotropic. Its effects involve anxiolytic effects, possibly through the GABAnergic system or the GABA system of the brain, and immune modulation. Dr. Deb Muth 52:44The Russian research is examined by C-Link for anxiety disorders. and finding reductions in anxiety without sedation. There is a dependency potential or cognitive impairment does not exist like it does with benzodiazepines with C-Link. So that is really good. And they do report attention and memory improvement using C-Link. There is a study that was done in neuroscience and behavioral psychology in 2018 that examined C-Linx effects and proposed that it exerts cytoprotective effects through BDNF pathways similar to C-Max. So both of these are Russian research-based They’re not wrong or fraudulent. It’s just that they are from Russia and we all have our concerns with Russia. However, that does not necessarily mean their research doesn’t hold quality. Dr. Deb Muth 53:49Neither peptide is approved by the FDA, and so you are using this off-label. The same rules apply for all of the other peptides that we’ve talked about that are produced off label. You want to do the same things that you would do with anything else. Good protein, omegas, B vitamins, acetylcarnitine, exercise, sleep, all of that still applies when we’re using these peptides. So I want to talk briefly about clinical decision and framework when we’re looking at this. First and foremost, we always want to go to FDA-approved peptides. Secondly, we would look at international approval with peptides that are established in other countries but lack FDA approval. And then preclinical evidence only or experimental peptides. These can be used, but they are not ethically recommended in the traditional medicine world. Dr. Deb Muth 54:50 If patients use them, we need to have appropriate counseling about the evidence surrounding them, the safety, and where to find them. how to find them and how to ask for these certificates of analysis. So I think it’s really good that we were exploring all these peptides and understanding what they are. There’s a lot of controversy out there. There’s a lot of concern out there. And what we can say with confidence is that peptides are powerful biological signaling molecules. Some peptide based medications, semi-glutide, triseptide, PT 141, Lupron that are all FDA approved. can dramatically improve outcomes in patients that are obviously selected for the correct ones. There are many other peptides that we address that are integrative and longevity space in the regenerative medicine. These peptides are all experimental. That does not automatically make them wrong. Dr. Deb Muth 55:50It just means that we need to be honest about what we’re doing with them and we need to be cautious with the patients so that they can make a decision to be part of an experimental study. in looking at how to use these peptides. So peptides are tools like any other tools. They work best in the hands of skilled people, and they are applied to appropriate situations, integrating into comprehensive approaches that address root causes. The most powerful peptide administered to a patient with untreated inflammation, hormonal chaos, nutritional deficiencies, and disorders of sleep will disappoint. The simplest evidence-based interventions apply. to a patient whose foundational physiology has been optimized. And this is the art of the science of peptide, right? If done right, respecting both the power of these molecules and the complexity of human beings that we are privileged to serve can make a difference in their lives. So thank you for listening to this episode. Dr. Deb Muth 56:52I hope this was helpful. If you can know of somebody that might benefit from this, please like, share, and subscribe. It means a lot to us. And I hope you join us for our next episode of Let’s Talk Wellness Now. Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided for informational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Dr. Deb Muth 57:54Your use of information from this broadcast is entirely at your own risk. By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 258 – Investigational Peptides: What's Promising, What's Hype & What You Must Know first appeared on Let's Talk Wellness Now.

Stjärnregissören Tomas Alfredson är bioaktuell med Lek med Alfons Åberg. P1 Kulturs Lisa Bergström undersöker vad som är hans egen relation till Alfons? Och till Gunilla Bergström? Lyssna på alla avsnitt i Sveriges Radios app. Tomas Alfredson är mest känd för filmer som dramaskräckisen ”Låt den rätte komma in”, Killinggängets ”Fyra nyanser av brunt” och spionthrillern ”Tinker, Tailor, Soilder, Spy”.Förra året gjorde han tv-serien ”Trolösa” i SVT. Men dessförinnan släppte sin första Bokfilm: "Aja baja, Alfons Åberg" (2022) - nu som då med Jonas Karlsson som berättare.Varför dras han till Alfons Åberg? Och vad är egentligen en ”bokfilm”?Dessutom, efter intervjun följer ett kritiksamtal om ”Lek med Alfons Åberg” med kulturredaktionens filmkritiker Nina Asarnoj.

Community Focus with Gregory T. Roberts and Melvin Burns II, featuring guest Blair Moreau, Director of Heart and Vascular Services, and Katie Alfredson, board-certified Adult-Gerontology Nurse Practitioner of Trinity Health, regarding their recent achievement, and Rob Mathis of Citi Boi Corp, regarding their services and events.

Astronomen och gymnasieläraren Anders Nyholm blir tamburmajor i marschens taktfasta historia när vi lyssnar på Wagner, Schubert, Lumbye, Alfvèn, Wollter, Ramel, Python, Demert och Alfredson. Begrepp att ta med sig: domänförlust och absolut musik. Lyssna på alla avsnitt i Sveriges Radio Play.

Daniel Alfredson har gjort det mesta man kan inom film nu ska han bli författare. I P4 Extra Gästen berättar han varför han ska hugga träd, om att djupdyka i kalla kriget och regissera pappa Hasse. Lyssna på alla avsnitt i Sveriges Radio Play.

Filmskapandet blev en kontaktannons till pappa Hasse och ett sätt att försöka göra sig förstådd. Vad vill Tomas Alfredson säga? Lyssna på alla avsnitt i Sveriges Radio Play. Han är en av våra mest kända och erkända filmregissörer och han har rört sig över genre-gränserna som få andra. På Tomas Alfredsons CV finns internationella spionsuccén Tinker, tailor, soldier, spy, vampyrdramat Låt den rätte komma in, Alfons Åberg-serier och Killinggängets hyllade Fyra nyanser av brunt och Torsk på Tallinn. Nu under vintern har du kanske sett hans nytolkning av Ingmar Bergmans och Liv Ullmans svartsjukedrama Trolösa på SVT.”Minns energin, inte hans faderskap”Trots till synes skarpa hopp mellan genrerna så kan man skymta ett återkommande tema i hans filmer; ett utforskande av ensamhet, utanförskap och mellanmänskliga relationer. Hur kommer det sig? Och hur var det att växa upp i skuggan av pappan Hasse Alfredson – i en relation som präglades av både kärlek och frånvaro?Programledare: Martin WicklinProducent: Filip BohmKontakt: sondagsintervjun@sr.se

Dans ce nouvel épisode d'En tendon, nous avons le grand plaisir de recevoir Blaise Dubois qui est notamment le Fondateur de La Clinique Du Coureur. Blaise nous a accordé deux entretiens pour votre plus grand bonheur. Un premier orienté sur les douleurs, les tendons et la course à pied. Un second davantage orienté sur l'épanouissement et les doutes professionnels ! Au programme de ce premier épisode : Présentation de BlaiseLa cryothérapie en 2024, utile ou futile ?Comment gérer l'équilibre entre la science et les croyances ?L'importance du contexte Donc, la cryothérapie, on en fait quoi ?L'influence des attentes du patient Le dénominateur commun à toutes les pathologies de surcharge Un concept crucial à comprendre Le renforcement musculaire pour mieux courir ? Comment expliquer les performances des coureurs Kenyans ? Combien de fois faut-il courir hebdomadairement ? Un peu vaut mieux que rien du tout ? Le tendon est con, pourquoi ? Stanish, Silbernagel, HSR, Alfredson… que choisir ? Jongler entre l'idéal et le possible Le trop, l'ennemi du bien en rééducation ? Et comme d'habitude, si tu as aimé ce podcast, le meilleur moyen pour nous le faire savoir c'est de noter cet épisode et/ou de partager le podcast autour de toi, car c'est grâce à toi qu'En tendon grandit chaque jour, donc merci pour ton écoute et ton soutien, c'est essentiel pour nous !_________________BONUS : Accédez à des milliers de ressources et outils utiles pour votre pratique clinique en kinésithérapie sur https://www.fullphysio.com/_________________À propos d'En tendon :Chez Fullphysio nous cherchons continuellement à aider les kinésithérapeutes dans l'élaboration de traitements optimaux !L'objectif : contribuer, à notre niveau, à l'amélioration de la santé des populations.Pour cela, nous mettons à la disposition des milliers de kinésithérapeutes utilisateurs de fullphysio.com des ressources et outils utiles pour leur pratique clinique de la kiné. Mais nous souhaitions aller au-delà de l'aspect "clinique et scientifique".C'est la raison pour laquelle en janvier 2024 nous avons lancé "En tendon", le podcast des kinés !Notre but avec "En tendon" : Aider les kinés à s'épanouir dans leur métier en s'inspirant de ce que font les meilleurs spécialistes de la sphère médicale.Pour cela, Augustin Castel, kinésithérapeute du sport passionnés, invite deux fois par mois des professionnels de santé inspirants pour échanger à propos de leur manière de pratiquer et partager leurs retours d'expériences.N'hésitez pas à partager les épisodes autour de vous et à ajouter un avis sur vos plateformes d'écoutes préférées !Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Kulturjournalisten Sofia Lilly Jönsson, själv AF-alumn, listar, dementerar och bekräftar fördomar hon tror folk har om den mytomspunna Stockholmsskolan Adolf Fredrik. Namn nämns en masse: Brännström, Häggkvist, Alfredson, Riedel, Wahlgren, Björklund, Guve, Al Fakir, Körberg och Anka. Tage Danielssons Sopor missas helt. Lyssna på alla avsnitt i Sveriges Radio Play.

Pour ce nouvel épisode, nous accueillons Pierre Oberkampf, compositeur et sound designer très prolifique côté courts métrages. Nous lui devons notamment toute l'identité sonore du césarisé “L'heure de l'ours” d'Agnès Patron. Avec nous, il évoque son rapport aux bandes originales et nous raconte son goût pour les compositions risquées voire improvisées, de celles de Jon Brion pour Gondry et Paul Thomas Anderson à la batterie d'Antonio Sanchez pour le Birdman d'Iñárritu. Il égraine aussi quelques uns de ses courts métrages préférés (Nuvole Mani de l'italien Simone Massi, J'entends ton cri de l'argentin Pablo Lamar). Mais surtout, il nous emmène vers des chemins buissonniers de cinéma où l'enfance est toujours présente avec ce qu'elle comporte de jeux, d'aventures (Mud, Moonrise Kingdom) et de violence (There Will be blood, Morse…) Inscrivez-vous à la newsletter en cliquant sur ce lien : https://forms.gle/HgDMoaPyLd6kxCS48 Pour nous soutenir, rendez-vous sur https://www.patreon.com/cinephilesdnt I. PORTRAIT - 4'44 Des enfants de cinéma : Antoine Doinel dans Les 400 coups (F. Truffaut, 1959); Eli et Oskar dans Morse (T. Alfredson, 2009); Ellis et Neckbone dans Mud (J. Nichols, 2012); Sam et Susie dans Moonrise Kingdom (W. Anderson, 2012) - 4'44 Une atmosphère : celle de Bright Star (J. Campion, 2009) - 9'14 Une violence au cinéma : celle de There Will be blood (P.T Anderson, 2007) II. CIRCONSTANCES & CONDITIONS DE VISIONNAGE - 18'43 Des courts métrages marquants : Nuvole, Mani (S. Massi, 2009); J'entends ton cri (Pablo Lamar, 2010) - 18'43 Des bandes originales pour sauter de son fauteuil : celle de Jon Brion pour Eternal Sunshine of the spotless mind (M. Gondry, 2004); celle d'Antonio Sanchez pour Birdman (A. Iñárritu) - 26'15 III. MEMOIRE & SOMMEIL - 31'52 Un film que Pierre aurait aimé rêver : Eternal Sunshine of the spotless mind (M. Gondry, 2004) CARTE BLANCHE - 36'31 There Will be blood (P.T Anderson, 2007) TRANSMISSION - 45'55 Une bande originale improvisée à faire connaître : celle de Alex Zhang Hungtai pour Godland (H. Palmason, 2022) Un film à transmettre aux adolescents : Two Lovers (J. Gray, 2008) - 49'57 REFUGES - 54'12 Les filmographies d'Aki Kaurismaki et de Wes Anderson EXTRAITSL'heure de l'ours, Pierre OberkampfLes derniers feux, Pt. 1, Pierre OberkampfTheme, Jon Brion (from Eternal Sunshine of the spotless mind), Hollywood records, incTheme from Godland, Alex Zhang Hungtai (Jour2fête) CRÉDITSPatreons : un grand merci à Paul, Corentin, Irène, Dominique, Bernard et Clara pour leur soutien !Musique : Gabriel Rénier, Pierre OberkampfGraphisme : Lucie AlvadoCréation & Animation : Phane Montet & Clément Coucoureux

If you are from Vancouver, congrats you finally got what you deserved and woah, look around, nothing is on fire. Wow, beautiful. We can have good things. Anywho, one love to the Sedin Twins and Roberto Luongo for being validated and more importantly being validated off the rip. Not everyone in the Hall are first ballot Hall of Famers but damn, you three are. 

Book: Let the Right One In By John Ajvide Lindqvist ​ Film: Let the Right One In (2008)   The story centers on the relationship between a 12-year-old boy, Oskar, and a centuries-old vampire child, Eli. It takes placein Blackeberg, a working-class suburb of Stockholm, in the early 1980s. The book focuses on the darker side of humanity, dealing with thematically heavy issues such as existential anxiety, social isolation, fatherlessness, divorce, alcoholism, school bullying, paedophilia, genital mutilation, self-mutilation, and murder.   Swedish romantic horror film directed by Tomas Alfredson, based on the 2004 novel of the same title by John Ajvide Lindqvist, who also wrote the screenplay.  film adaptation of Lindqvist's novel began development in 2004 when John Nordling acquired the rights to produce the project. Alfredson, unconcerned with the horror and vampire conventions, decided to tone down many elements of the novel and focus primarily on the relationship between the two main characters and explore the darker side of humanity.   We are joined by novelist Matthew Brockmeyer and writer, director, producer and novelist C. Derick Miller.   Opening Credits; Introduction (1.44); Plot Synopsis (15.44); Forming the Plot (17.53); Book Thoughts (23.39); Scoring The Book (1:26.19 ); Introducing a Film (1:36.10); Film Trailer (1:37.52);  Lights, Camera, Action (1:39.35); Epilogue (2:50.56); End Credits (2:54.17); Closing Credits (2:57.09)   Opening Credits– Classical Jingle by Dan Hughes   Closing Credits – Let Me In by Laura Branigan.  Taken from the album Laura Branigan. Copyright 1990 Atlantic Records   Original Music copyrighted 2020 Dan Hughes Music and the Literary License Podcast.    All songs used by kind permission.   All rights reserved.   All songs available through Amazon.    

Today we wrap up our interview with Adam Alfredson.  He shares how he moves on from heartache while working with youth.  He also talks about how his and his wife's new ministry EVEN IF...MINISTRIES was born.  If you missed the first 2 parts of the interview, go back and listen to Episodes 41 and 42.As Always,Keep Showing Up & Keep Caring!Deb

On today's episode, I continue my interview with fellow youth worker, Adam Alfredson.  He talks about how he connects and builds relationships with youth.  He also offers insight in how he avoids ministry burnout.  As Always,Keep Showing Up & Keep Caring!

On today's podcast, I interview fellow youth worker Adam Alfredson.  He shares his own story of faith and a little bit about where he serves youth.  This is part 1 of a 3 part interview.As Always,Keep Showing Up & Keep Caring!Deb

In the wake of the excitement over No Time to Die, Mike and Dan take a look at a much different kind of spy thriller, Tomas Alfredson's "infuringly brilliant" 2011 adaptation of Tinker Tailor Soldier Spy.  After acknowledging the film's complexity and the idea that "many first dates must have been ruined by this movie," Mike and Dan explain how the film teaches its viewers to think like a spy, how the film flips the usual motives seen in spy thrillers, and what makes for a perfect adaptation, as they think Alfredson's is.  Of course, they compare it to the 1979 miniseries with Alec Guinness, heaping praise upon each.  So give Karla your lighter, go for a swim, and join the guys for a conversation about a film they find fascinating and rewatchable.    Please subscribe to the show wherever you get your podcasts and follow us on Twitter @15MinFilm and on Facebook at Fifteen Minute Film Fanatics.   Rate and review the show on Apple podcasts, and contact us at FifteenMinuteFilm@gmail.com.  We take requests!  You can also support the show with a buck or two at Venmo @FifteenMinuteFiIm.  We'll use any donations to buy half and half at Ralph's.   Incredible bumper music by John Deley.

Today, Brodie tells the tale of Dr. Alfredson, a Swedish surgeon back in the 1990's who mistakenly discovered the benefits of eccentric loading exercises for tendon rehabilitation. He would later develop the Alfredson eccentric protocol which is widely accepted and performance up to the present day. After sharing this story, Brodie reflects on the rehabilitation of Proximal Hamstring Tendinopathy and 3 key takes aways from Alfredson's experience that can help you. Click here to learn more about the PHT video course & to receive your 50% discount If you would like to learn more about having Brodie on your rehab team go to www.runsmarter.online  Or book a free 20-min physio chat here

Ahir el Doctor Jordi Ardèvol ens donava el seu punt de vista sobre la lesió de Ter Stegen, avui al 'Què t'hi Jugues!' hem pogut saber de primera mà com és aquesta lesió i quines impressions té el mateix doctor que operarà al porter del Barça. El Doctor Hakan Alfredson ha passat pels micròfons de SER Catalunya per fer dos apunts previs a la intervenció a la qual se sotmetrà Marc André Ter Stegen en el dia de demà a Malmö.

This episode takes us from podcasters to master sleuths: join us as we open the case file on Tomas Alfredson's detective and spy movies The Snowman (2017) and Tinker Tailor Soldier Spy (2011). After commiserating over (and finding the value in) Alfredson’s notoriously meme-ified flop, we share our admiration for Alfredson’s nuanced, taut adaptation of the classic spy novel by John Le Carré. Want to give us all the clues? Drop them in mysterious notes on our Discord! For 50% off your first 3 months of OVID.tv, use code “DEEPCUT” at check-out.

Auch wenn man mit Sehnenerkrankungen nichts anfangen kann, Tennis- oder Golferellenbogen hat jeder schon einmal gehört oder? Gerade in unserer sportlichen Community sind deutlich mehr Leute betroffen, als man so denkt und dazu gibt es jetzt die Fakten. Viel Spaß! 0:52 Vendée Globe Update 2:30 Einführung in die Tendinopathien 6:39 Golfer- und Tennisellenbogen 9:20 Zurück zur Bewegung 10:28 Was passiert im Gewebe ? 19:02 Reaktion auf Belastung 23:45 Wer ist betroffen? 25:30 Selbsttest 27:57 Mit Sehnenerkrankungen richtig umgehen 29:10 Krafttrainingsprogramme in der Reha 32:57 Die 6 Phasen der Rehabilitation 38:43 Fazit ------------------------------------------------ Wenn euch die Folge gefallen hat, dann teilt sie mit euren Freunden. Abonniert uns bei Spotify und Apple Podcast, damit ihr keine Folge verpasst. Wir hören uns wieder am nächsten Montag. Startet gut in die Woche! Instagram ToL: https://www.instagram.com/trainingohnelimit Instagram Silvan: https://www.instagram.com/silvanschlegelpt Instagram Hendrik: https://www.instagram.com/hendrik_senf ------------------------------------------------ Literaturnachweise: Scott, A., Squier, K., Alfredson, H., Bahr, R., Cook, J. L., Coombes, B., Zwerver, J. (2019). ICON 2019: International Scientific Tendinopathy Symposium Consensus: Clinical Terminology. British Journal of Sports Medicine, bjsports–2019–100885. Docheva, D., Müller, S. A., Majewski, M., & Evans, C. H. (2015). Biologics for tendon repair. Advanced Drug Delivery Reviews, 84, 222–239.

Daniel guests on the latest episode of FILM SCHOOL PROFESSIONALS with your favorite Slow Readers guests: Katie "Chaos" Kametz and "Black Metal" Malu Mirones!! So check it out, and then subscribe and listen to all the Film School Professionals episodes RIGHT MEOW!! *** Buckle up, class, we're talkin' sex, spies, and style in two of the horniest films about espionage ever made! Professors Katie and Malu welcome writer and audio producer Daniel Gonzalez (@slowreaders) of the Slow Readers podcast to get itchy with Ritchie and all red, son, with Alfredson! Daniel brings Guy Ritchie's The Man From U.N.C.L.E. (2015) and Tomas Alfredson's Tinker Tailor Soldier Spy (2011) to the table. Tangents galore, codenames, and general thirst ensues. It was the war, students. Please rate, review, and subscribe on your podcatcher of choice, you dirty moles! Professor Katie's Short Film: https://www.youtube.com/watch?v=kXpJ5A0JSrY Instagram: @filmschoolprofessionals Professor Malu's Art Instagram: @malusdoodles Professor Katie's Instagram: @_katiee_kat

Buckle up, class, we're talkin' sex, spies, and style in two of the horniest films about espionage ever made! Professors Katie and Malu welcome writer and audio producer Daniel Gonzalez (@slowreaders) of the Slow Readers podcast to get itchy with Ritchie and all red, son, with Alfredson! Daniel brings Guy Ritchie's The Man From U.N.C.L.E. (2015) and Tomas Alfredson's Tinker Tailor Soldier Spy (2011) to the table. Tangents galore, codenames, and general thirst ensues. It was the war, students. Please rate, review, and subscribe on your podcatcher of choice, you dirty moles! Professor Katie's Short Film: https://www.youtube.com/watch?v=kXpJ5A0JSrY Instagram: @filmschoolprofessionals Professor Malu's Art Instagram: @malusdoodles Professor Katie's Instagram: @_katiee_kat

Vi får besök utav en av Sveriges mest framgångsrika regissörer Tomas Alfredson, just nu aktuell med en egen tolkning av kulttrion Jönssonligan. Vi pratar om varför han kritiserat att filmen inte går upp på bio, hur hans internationella framgångar påverkat hans registil, hur han ser på mångfald i filmvärlden och när hans drömprojekt - en remake av Bröderna Lejonhjärta egentligen ska bli av.

Katherine är tillbaka från julledigheten, det ryktas om skilsmässa för Kim och Kanye, det är beef mellan två hiphop-giganter och en man har vunnit ett märkligt fall i hyresnämnden tack vare sin älskarinna. En händelserik onsdagsmorgon med andra ord! Stjärnregissören, tillika Kalle Bergs drömgäst, Tomas Alfredson kommer till studion men det gör tyvärr inte Kalle. Istället ringer vi upp Kalle som ger oss ett par frågor vi helt enkelt måste ställa till Tomas.

Is it time to make a change in your professional or business life?  David Vallieres is joined by Daniel Alfredson, Vice President of Client Services at Synergy Capital Solutions to discuss the tough questions that need to be answered when starting, expanding or exiting your business In this episode, you will learn: The types of … Continue reading Taking the Next Steps in Business — with Guest Daniel Alfredson →

Continuing their retrospective episodes on horror remakes released in 2010 that celebrate their 10th anniversaries this year, Horror BFFs Heather Wixson and Patrick Bromley take a look back at Matt Reeves' reimagining of Tomas Alfredson's Let the Right One In (based on John Ajvide Lindqvist's novel of the same name) on this episode of Daily Dead's official podcast!    Listen as Heather and Patrick have an in-depth discussion on 2010's Let Me In, including its haunting coming-of-age story, its depiction of young love and vampirism, how it compares to Alfredson's Swedish film, and its memorable performances by a talented cast including Kodi Smit-McPhee, Chloë Grace Moretz, Elias Koteas, and Richard Jenkins.    So, whether you've already sunk your teeth into this 2010 remake or you've never experienced its immortal horrors before, sit back, relax, and enjoy a new Horror BFFs episode of Corpse Club!

Many consider the 1979 mini-series adaptation of John le Carré's "Tinker Tailor Soldier Spy" to be not only the definitive le Carré adaptation but also that Alec Guinness to be the definitive George Smiley. Because of that, tackling the story again can be seen as a tricky task. Luckily, the team behind the film adaptation in 2011 found the right people to adapt the script, the right director to helm it, and the perfect actor to fill Guinness' shoes. Join us – Pete Wright and Andy Nelson – as we wrap up our John le Carré series with Tomas Alfredson's 2011 film Tinker Tailor Soldier Spy. We talk about why Gary Oldman works so well in this part and how quiet his performance is. We look at the way the story is crafted and compare it to last week's film, looking at why this adaptation works and that one doesn't. And we look at the style Alfredson brought to the film. It's a great film and one we have a great time chatting about. Check it out then tune in to this week's show! The Next Reel – when the movie ends, our conversation begins. Join the conversation with movie lovers from around the world on The Next Reel’s Discord channel! Film Sundries Watch this film: iTunes • Amazon • Netflix • YouTube Script Transcript Original theatrical trailer Original poster artwork Tinker, Tailer, Soldier, Spy: A George Smiley Novel by John le Carré Flickchart Letterboxd

Many consider the 1979 mini-series adaptation of John le Carré's "Tinker Tailor Soldier Spy" to be not only the definitive le Carré adaptation but also that Alec Guinness to be the definitive George Smiley. Because of that, tackling the story again can be seen as a tricky task. Luckily, the team behind the film adaptation in 2011 found the right people to adapt the script, the right director to helm it, and the perfect actor to fill Guinness' shoes. Join us – Pete Wright and Andy Nelson – as we wrap up our John le Carré series with Tomas Alfredson's 2011 film Tinker Tailor Soldier Spy. We talk about why Gary Oldman works so well in this part and how quiet his performance is. We look at the way the story is crafted and compare it to last week's film, looking at why this adaptation works and that one doesn't. And we look at the style Alfredson brought to the film. It's a great film and one we have a great time chatting about. Check it out then tune in to this week's show! The Next Reel – when the movie ends, our conversation begins. Join the conversation with movie lovers from around the world on The Next Reel's Discord channel! Film Sundries Watch this film: iTunes • Amazon • Netflix • YouTube Script Transcript Original theatrical trailer Original poster artwork Tinker, Tailer, Soldier, Spy: A George Smiley Novel by John le Carré Flickchart Letterboxd

IKSUpodden - av medlemmar för medlemmar, tillsammans med Johan Asplund och Malin Forsberg.I dagens avsnitt testar vi Inner Strength och gästas sedan av Håkan Alfredson, läkare och världsledande forskare inom häl- och knäskålssena. 2019 mottog Håkan IKSUs idrottsvetenskapliga pris till minne av Jan Åman. I podden berättar Håkan om olika patientmöten, hur han hjälpte Zlatan med sin knärehab och hur det kom sig att han i ren frustration efter en konflikt med sin chef bestämde sig för att försöka slita av sig sin egen hälsena. Allt detta och mycket mer hör du i avsnitt 17 med Håkan Alfredsson. Har du frågor eller tips till IKSUpodden, hör då av dig till iksupodden@gmail.com eller IKSUpoddens instagram @iksupodden.

Welcome to an LRM Online Podcast Network exclusive interview with the director of Intrigo: Death of an Author, Daniel Alfredson. Intrigo: Death of an Author is the first film in a series set in a fictional European setting that are all connected by people and the cafe Intrigo. These films are based on the best selling novels from Håkan Nesser. Please, like share and subscribe!

Uppläsning: Hans Alfredson (ur Sveriges Radios arkiv) Önskad av: Anders Hyléen Diktsamling: "Blomstervers" (1996) MUSIK Erik Satie: Gymnopédie nr 3. EXEKUTÖR Carlos Barbosa-Lima, gitarr

Det har återigen blivit dags för en intervju hos Cyklisterna podcast. Denna gången är gästen ingen mindre än Per Alfredson, Mr Sensa! Lyssna på ett samtal som handlar om västgötaslätten, att vilja ha något unikt och hur man vågar och lyckas med ett eget cykelmärke. Ni hittar Pers cyklar här. Sitter du på en möjlighet att förverkliga Pers dröm om att driva ett cykelteam, helst på MTB? Hör av er till oss så ska vi förmedla kontakt. Eller ja, det går ju bra att kontakta Per direkt också, han har ju Sveriges näst bästa öppettider! Mycket nöje!

www.alisonartisan.com They can contact me via Facebook or Instagram. Direct email messages are also welcome. https://www.facebook.com/AlisonArtisanFineArt/ or https://www.instagram.com/alison.alfredson.art/

"I'm a survivor, as you should know by now." Stieg Larsson had plans to write an entire series of Millennium novels, but unfortunately died having only written three of them. Because of this, they're often referred to as the Millennium trilogy. Sure, they have the same characters largely and are centered around the Millennium magazine, but it's not really a trilogy per se. That being said, when making the three films, it didn't stop the team from shooting them all back to back to keep the story as cohesive as possible. While it's great having the three Swedish films feel so much of a whole, it is a challenge seeing this as a trilogy. It doesn't help that the third film, Daniel Alfredson's 2009 The Girl Who Kicked the Hornets' Nest, starts to feel a bit like the storytellers are stretching credulity a bit. Join us – Pete Wright and Andy Nelson – as we wrap up our series on the Millennium ‘trilogy' with Alfredson's film. We talk about the basic struggles we have with the film, even if we still largely enjoy it. We look at the struggles all trilogies seem to face and how that often is expounded when they shoot them back to back. We talk about the cast and how well they do, most notably the women throughout. We look at the courtroom scene and Dr. Teleborian's takedown, discussing the camerawork and performances and how that scene stands out as quite effective. And we come back around to talking about Noomi Rapace and Michael Nyqvist and how great they are in their roles. While we have issues with this film, it's still one we enjoy and would return to. It's a series of films that's dark but definitely worth checking out. So check it out! Then tune in. The Next Reel – when the movie ends, our conversation begins. Film Sundries Thank you for supporting The Next Reel Film Podcast on Patreon! — https://patreon.com/thenextreel Watch this film: iTunes • Amazon • Netflix Swedish trailer US trailer Original poster artwork The Girl Who Kicked the Hornet's Nest — Comixology The Girl Who Kicked the Hornet's Nest by Stieg Larsson Flickchart Letterboxd

"I’m a survivor, as you should know by now." Stieg Larsson had plans to write an entire series of Millennium novels, but unfortunately died having only written three of them. Because of this, they’re often referred to as the Millennium trilogy. Sure, they have the same characters largely and are centered around the Millennium magazine, but it’s not really a trilogy per se. That being said, when making the three films, it didn’t stop the team from shooting them all back to back to keep the story as cohesive as possible. While it’s great having the three Swedish films feel so much of a whole, it is a challenge seeing this as a trilogy. It doesn’t help that the third film, Daniel Alfredson’s 2009 The Girl Who Kicked the Hornets’ Nest, starts to feel a bit like the storytellers are stretching credulity a bit. Join us – Pete Wright and Andy Nelson – as we wrap up our series on the Millennium ‘trilogy’ with Alfredson’s film. We talk about the basic struggles we have with the film, even if we still largely enjoy it. We look at the struggles all trilogies seem to face and how that often is expounded when they shoot them back to back. We talk about the cast and how well they do, most notably the women throughout. We look at the courtroom scene and Dr. Teleborian’s takedown, discussing the camerawork and performances and how that scene stands out as quite effective. And we come back around to talking about Noomi Rapace and Michael Nyqvist and how great they are in their roles. While we have issues with this film, it’s still one we enjoy and would return to. It’s a series of films that’s dark but definitely worth checking out. So check it out! Then tune in. The Next Reel – when the movie ends, our conversation begins. Film Sundries Thank you for supporting The Next Reel Film Podcast on Patreon! — https://patreon.com/thenextreel Watch this film: iTunes • Amazon • Netflix Swedish trailer US trailer Original poster artwork The Girl Who Kicked the Hornet’s Nest — Comixology The Girl Who Kicked the Hornet’s Nest by Stieg Larsson Flickchart Letterboxd

"Hello, Papa." Stieg Larsson’s second novel in the Millennium trilogy, “The Girl Who Played With Fire,” saw the continuation of the story of Lisbeth Salander and Mikael Blomqvist while they try to stop a sex trafficking ring in Sweden. The whole trilogy of books was a massive success, but the film version was given half the budget of the first film for some reason, while also being paired with a different director. Perhaps the producers knew the book wasn’t quite as good as the first one? Perhaps they figured they could spend less because people would be seeing it anyway? Whatever the reasons, it seems a bit like the ugly red-headed stepchild. But director Daniel Alfredson still put together an effective film, even if it feels a bit average at times. Join us – Pete Wright and Andy Nelson – as we continue our series on the Millennium trilogy with Alfredson’s 2009 take on The Girl Who Played With Fire. We talk about the overall feel of the film and try to gauge why it doesn’t feel as fresh or original as the first film. We discuss the inevitable effects that a much lower budget has on those making the film and ponder if that affected Alfredson. We debate about Alfredson as a director and wonder what he’s bringing to the table. We are still thrilled with Noomi Rapace and Michael Nyqvist as Lisbeth and Mikael, even if there are elements about them that can be more frustrating here. We look at Peter Mokrosinski’s cinematography and look at where it works and where it doesn’t. And we look at the script and how the adaptation works, questioning whether some of the poorer elements were thrust on the filmmakers by Larsson’s source material. On the whole, we enjoy the film but not on the level of the first entry. Still, it allows for a great conversation, so check it out then tune in! The Next Reel – when the movie ends, our conversation begins.  Film Sundries Thank you for supporting The Next Reel Film Podcast on Patreon! — https://patreon.com/thenextreel Watch this film: iTunes • Amazon • Netflix Original theatrical trailer US Red Band trailer The Girl Who Played with Fire by Stieg Larsson Flickchart Letterboxd

"Hello, Papa." Stieg Larsson's second novel in the Millennium trilogy, “The Girl Who Played With Fire,” saw the continuation of the story of Lisbeth Salander and Mikael Blomqvist while they try to stop a sex trafficking ring in Sweden. The whole trilogy of books was a massive success, but the film version was given half the budget of the first film for some reason, while also being paired with a different director. Perhaps the producers knew the book wasn't quite as good as the first one? Perhaps they figured they could spend less because people would be seeing it anyway? Whatever the reasons, it seems a bit like the ugly red-headed stepchild. But director Daniel Alfredson still put together an effective film, even if it feels a bit average at times. Join us – Pete Wright and Andy Nelson – as we continue our series on the Millennium trilogy with Alfredson's 2009 take on The Girl Who Played With Fire. We talk about the overall feel of the film and try to gauge why it doesn't feel as fresh or original as the first film. We discuss the inevitable effects that a much lower budget has on those making the film and ponder if that affected Alfredson. We debate about Alfredson as a director and wonder what he's bringing to the table. We are still thrilled with Noomi Rapace and Michael Nyqvist as Lisbeth and Mikael, even if there are elements about them that can be more frustrating here. We look at Peter Mokrosinski's cinematography and look at where it works and where it doesn't. And we look at the script and how the adaptation works, questioning whether some of the poorer elements were thrust on the filmmakers by Larsson's source material. On the whole, we enjoy the film but not on the level of the first entry. Still, it allows for a great conversation, so check it out then tune in! The Next Reel – when the movie ends, our conversation begins.  Film Sundries Thank you for supporting The Next Reel Film Podcast on Patreon! — https://patreon.com/thenextreel Watch this film: iTunes • Amazon • Netflix Original theatrical trailer US Red Band trailer The Girl Who Played with Fire by Stieg Larsson Flickchart Letterboxd

Tendinopathy patients may present for treatment with an ultrasound or MRI report in hand, unsure how you can help them, or how they can possibly recover when they have so much tendon pathology. To add insult to injury, they may even have a partial tendon tear on their imaging report thrown into the mix. How do imaging results impact your treatment and your patient's recovery? Are the imaging findings relevant to their pain? In this Physio Edge podcast with Dr Sean Docking (Physiotherapist, PhD), you will explore what information imaging actually provides in your tendinopathy patients, how to explain imaging to your patients, and whether partial tendon tears identified on imaging will effect your treatment. You will also discover: Who develops tendon pathology If patients have tendon pathology on imaging, is this responsible for their symptoms, or will it cause future tendon pain Asymptomatic tendon pathology in sports people How tendon pathology can actually be linked to better performance Can we prevent tendon pathology The advantages and disadvantages of different imaging types, including MRI Ultrasound Ultrasound tissue characterisation (UTC) Why a thickened tendon may actually be helpful in recovery How can we actually diagnose tendinopathy When is imaging useful Differential diagnosis of Achilles pain, including Achilles tendinopathy Paratenonitis Plantaris associated tendinopathy Partial tendon tears, the accuracy of identification, and how they impact your treatment Sports injuries virtual conference As mentioned in this episode Sean presented at the 2017 Sports Injuries virtual conference. His main conference presentation on tendinopathy and imaging discusses: The research around the use for imaging A framework for when and when not to use imaging How to explain imaging findings to patients You can get immediate access to his presentation, and presentations from 13 of the leaders in sports injuries by CLICKING HERE Download this podcast and subscribe on iTunes   Links associated with this episode: Get your free access to Sports Injuries presentations with Dr Ebonie Rio, Jack Hickey, Dr Adam Weir, Dr Michael Rathleff, Jo Gibson and Prof Bill Vicenzino Enrol on the 2017 Sports Injuries virtual conference Twitter - @SIDocking Sean Docking - La Trobe University website Sean Docking - Research gate David Pope on Twitter Clinical Edge on Facebook Have a free trial Clinical Edge membership Articles associated with this episode: Alfredson. 2011. Midportion achilles tendinosis and the plantaris tendon Brown et al. 2011. The COL5A1 gene, ultra-marathon running performance and range of motion Docking et al. 2016. Pathological tendons maintain sufficient aligned fibrillar structure on ultrasound tissue characterization (UTC). Docking et al. 2015. Tendinopathy: Is imaging telling us the entire story? Lieberthal et al. 2014. Asymptomatic achilles tendinopathy in male distance runners McAuliffe et al. 2016. Can ultrasound imaging predict the development of Achilles and patellar tendinopathy? A systematic review and meta-analysis Simpson et al. 2016. At What Age Do Children and Adolescents Develop Lower Limb Tendon Pathology or Tendinopathy? A Systematic Review and Meta-analysis Other episodes of interest: PE 068 - Lower limb tendinopathy loading, running and rehab with Dr Pete Malliaris PE 042 - Treatment of Plantaris and achilles tedninopathy with Seth O’Neil PE041 - Plantaris involvement in achilles tendinopathy with Dr Christoph Spang

Trevor and Steven record their thoughts immediately after seeing The Snowman (2017). Yes we were buzzed and yes it was a bad movie, but you just don't understand how bad until you've seen it for yourself.

I get left out in the cold with The Snowman and debate the enormity of time with David Lowery's A Ghost Story. And later, I discuss the first trailer for Paul Thomas Anderson's upcoming Phantom Thread starring Daniel Day-Lewis. Follow the show on Twitter: @thecinemaspeak Intro: 0:00 - 6:46 Review - The Snowman: 6:46 - 32:19 Review - A Ghost Story: 32:19 - 45:07 News - Phantom Thread trailer: 45:07 - 50:50 This week in new releases/Outro: 50:50 - 54:01

Filmatiseringen av "Snømannen" har skapt debatt denne uken. Vi serverer vår dom over filmen og sammenligner filmen med boka for å se hva som fungerer og hva som mangler. Vi har også møtt regissøren og hovedrolleinnehaverne. Du får Birger Vestmos intervju med Tomas Alfredson, Michael Fassbender og Rebecca Ferguson.

P1 Kulturs Måns Hirschfeldt minns kultur- och nöjesikonen Hans Alfredson med hjälp av bland andra komikern och radioprofilen Annika Lantz och kulturredaktionens kritiker Anneli Dufva. Det är en utmaning att ringa in Hans Alfredsons gärning. Han var en extremt mångsidig entertainer, författare och filmregissör. Komikern och radioprofilen Annika Lantz väljer en sketch som inspirerat henne. Dramaturgen och kritikern Sven Hugo Persson pratar om Hans Alfredson och folkhemmet via sketchen "Ringaren" ur Gröna Hund. Kulturredaktionens kritiker Anneli Dufva tar sig an Hans Alfredson och filmen. Programledare: Måns Hirschfeldt Producent: Anna Tullberg

Vi pratar om Hasse Alfredson och hans verk. Peter Pluntky, svensk antikexpert, berättar om speldosan. Simone Giertz gästar för att prata knasiga uppfinningar och sitt nya program med Nisse Hallberg!

01/07/17 JIM ALFREDSON HAMMOND by Successful Living ShowSee omnystudio.com/listener for privacy information.

Livet är som en påse, tomt och innehållslöst om man inte fyller det med nåt, sa pastor Jansson i revyn Gröna hund 1962. Upphovsmannen till citatet, Hasse Alfredson, har fyllt sin påse till brädden. Författare. Regissör. Skådespelare. Revymakare. Skansenchef. Hasse Alfredson kan välja och vraka mellan titlarna även om han länge föredrog att beskriva sig som "en som skriver".1961 bildade han tillsammans med Tage Danielsson Aktiebolaget Svenska Ord. Deras samarbete skulle fortsätta tills Tages död 1985. Hasseåtage i ett ord blev ett begrepp och tillsammans skulle de dominera svensk underhållning i ett par decennier.Länge ansågs Hasse Alfredson som Sveriges roligaste man, men han har också velat skildra livets mörkare sidor. Som ondskan i filmen "Den enfaldige mördaren."Producent Rigmor Ohlsson.

Professor Hakan Alfredson Podcast by MACP

Whether to opt for exercise treatment, new ‘biological therapies' like platelet-rich plasma (PRP), or surgery is a clinical challenge. Sweden's Professor Håkan Alfredson has unique experience in considering these options for patients with Achilles pain. He has 15 years experience as an international leader in sports and exercise medicine. In this podcast, he tells BJSM's editor Karim Khan how to manage both straightforward (0.37) and complicated (7.34) Achilles tendinopathy. He shares novel insights into the contribution of the aberrant plantaris tendon to chronic medial leg pain (12.40). Prof Alfredson also provides a memorable clinical story to underscore the effectiveness of heavy loading eccentric training in one particularly stubborn patient (3.49). He argues against the use of PRP (17.37) and considers cortisone to be a short-term fix but long-term liability (15.24). The podcast concludes with discussion of both jumper's knee (19.35) and lateral elbow tendinopathy (24.44). Related paper: Midportion Achilles tendinosis and the plantaris tendon http://bit.ly/11y79bc Related podcasts: Robert Jan de Vos and Adam Weir on platelet rich plasma injections http://bit.ly/JdmFkJ Professor Jill Cook on managing tendinopathies in 2011 http://bit.ly/15DM8Qp

VSG's (the sports medicine society of the Netherlands) editor-in-chief Hans Tol and congress committee member Adam Weir highlight the October issue of BJSM and preview the VSG Annual Meeting on 1-2 December 2011. The first paper highlighted is from Collard et al [http://bit.ly/ZFQS3U], who have calculated the economic costs of organised sports, leisure time physical activities and physical education classes of 10-12 year old Dutch children (1.26). The outcomes are intriguing! A second paper of interest is from Malliaras and Cook [http://bit.ly/ZkULNj], who contend that the longitudinal changes in antero-posterior patellar diameter support a continuum of pathological changes (2.02). Two new theories on Achilles tendinopathy are presented in this issue. Firstly, Alfredson proposes [http://bit.ly/qyxi2W] there is an important role for the plantaris tendon (2.45). The second paper, presented by Andersson et al [http://bit.ly/15DwlRQ], highlights the role that substance P plays in tendinopathy (3.25). A must-read for those interested in tendon pathology and food for thought for all sport physicians! Visiting the VSG Annual Meeting in Kaatsheuvel, Netherlands, is a decision you won't regret. Hans Tol and Adam Weir explain in their warm-up why this is a must-visit for sports medicine enthusiasts. However, the conference language is Dutch, so make sure you master this in time! Dr Weir discusses the main topics of interest in the second half of the podcast (5.44).

Let us take you by the hand and lead you through the pages of John Le Carre's seminal spy novel, we'll show you something to make you change your mind about Tomas Alfredson's 2011 adaptation. We have to apologise in advance for the background noise on this, Thom is a fidget and can clearly be heard shuffling cards throughout a lot of this episode. Email us! backtothesourcepodcast@gmail.com

Mike, John, and Adam are running scared entertaing thoughts about Charlie Browns' parents and confusing vampire mythologies.If you have a comment or question you can write us at theaftershowpodcast@gmail.com or call and leave a voicemail message at (206) 984-1298.  Thanks for listening.LET ME IN imdb Page: http://www.imdb.com/title/tt1228987/LET THE RIGHT ONE IN imdb Page: http://www.imdb.com/title/tt1139797/

John, Mike, and Adam authorize the correct approach to second at bat.  Mostly so that they have a weapon to protect themselves from the Swedish felines.If you have a comment or question you can write us at theaftershowpodcast@gmail.com or call and leave a voicemail message at (206) 984-1298.  Thanks for listening.LET THE RIGHT ONE IN imdb Page: http://www.imdb.com/title/tt1139797/